Tweets
#ACR22 Abstr#0823 A systematic review which included 36 case series/report showed pulmonary manifestations are common in #VEXAS 56%. Unclear if due to VEXAS or previous disease which was misclassified. Longitudinal study with accurate & timely diagnosis could help @RheumNow https://t.co/ZJvmK2FWrI
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 8 months ago
Differentiation in UCTD? Abs 0328 finds puffy fingers, abnormal nailfold changes & SSc specific antibodies most predictive for UCTD progression to SSc. Younger age, serositis, +anti-dsDNA antibodies important for progression to SLE. #ACR22 @RheumNow https://t.co/DWL3V3dbFg https://t.co/fYHPOPdzfq
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Roongta et al. Small RCT of MTX+LEF vs MTX+RTX in RA. 21 patients each arm. No significant difference. @RheumNow #ACR22 Abstr#0931 https://t.co/jNDrMkkvhP https://t.co/dkfUnh5SM3
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Sulli et al. Concommittent folic acid delays MTX response, leads to greater doses of steroids and MTX. But more AEs when MTX without folic acid 32 vs 16% - nausea, transaminase elevations. @RheumNow #ACR22 Abstr#0930 https://t.co/jsUYG2YIZL https://t.co/YOpUbA4Ze9
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
IL17i Ixekizumab IXE improved spinal pain at night (SpN) in AxSpA, COAST V 52 wk study
◦ improvement greatest with younger age, HLA-B27+, high disease activity at baseline
◦ associated with improved BASFI, fatigue, SF36
Ramiro S Abs1009 https://t.co/GiCqg7W9IR #ACR22 @RheumNow
Dr. Antoni Chan @synovialjoints ( View Tweet )
3 years 8 months ago
Occupational inhaled agents increased risk of CCP+ RA, per Swedish occ data (OR 1.25, [1.12-1.38]). Dose-dependent increase in risk. Agents include quartz, asbestos, fungicides & carbon monoxide.
This is a common pt question!
@RheumNow ABST0601 #ACR22
https://t.co/QbsSLIXNar
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
Park et al. MTX discontinuation for 1 week post-influenza vaccine non-inferior to 2 week hold. Higher flare rate with 2 week hold. @RheumNow #ACR22 Abstr#0936 https://t.co/G53mcWFK2C https://t.co/VFY9TS5OIv
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Ab409 #ACR22 Bimekizumab (IL17A, IL17F) & PROs
P Mease on BE MOBILE 1 & 2
BKZ 160 mg q4w vs PBO
254 pts w nr-axSpA, 332 w AS
Improvement in spinal pain, nocturnal pain, morning stiffness, FACIT-FATIGUE for pts with AS and nr-axSpA, statistically signif diff at WK 16
@RheumNow https://t.co/nxZFSrb2XK
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Ab1044 #ACR22 Combined Biologic or Targeted Therapy (CBTT) in SpA
31 CBTT courses in 29 SpA pts - 69% also w IBD
Most common: TNF+IL12/23 or IL17
12 pts (38%) d/c CBTT - 7 inefficacy (5 2/2 IBD), 2 for AEs, 3 for other causes. 2 serious AEs (pulm infiltrates, staph ifn)
@RheumNow https://t.co/zExkpam0zK
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Reid et al. Safety of immune checkpoint inhibitor combo vs mono in pre-existing autoimmune disease. No significant difference. But 59% vs 32% for irAEs and 23% vs 10% for high grade irAEs @RheumNow #ACR22 Abstr#0757 https://t.co/UYhRM4xO9r https://t.co/r4NurxXzGZ
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Bilal et al. Increased risk VTE in aPL+ SLE patients on estrogen vs progesterone contraceptive. All forms progesterone appears equally safe (differs ACR guidance which does not recommended IM or implant) @RheumNow #ACR22 Abstr#0943 https://t.co/HGuZJgaRZQ https://t.co/KrIaKaYNTy
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
7pm ET on 11/13, join our SLE panel. #ACR22
https://t.co/B8XdaJFLS2 https://t.co/kqJRI2QRms
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
